Sun Pharm Drug Patent Portfolio

Sun Pharm owns 12 orange book drugs protected by 32 US patents with Bromsite having the least patent protection, holding only 1 patent. And Winlevi with maximum patent protection, holding 9 patents. Given below is the list of Sun Pharm's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10342850 Octreotide injection 15 May, 2038
Active
US10413525 Duloxetine sprinkles 13 Apr, 2037
Active
US10959982 Duloxetine sprinkles 13 Apr, 2037
Active
US11202772 Duloxetine sprinkles 13 Apr, 2037
Active
US9839626 Duloxetine sprinkles 13 Apr, 2037
Active
US10918694 Topical cyclosporine-containing formulations and uses thereof 28 Feb, 2037
Active
US11951153 Topical cyclosporine-containing formulations and uses thereof 28 Feb, 2037
Active
US10266523 Crystaline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-Methyl-4′-(trifluoromethoxy) [1,1′-biphenyl]-3-Methanamide monophosphate, and process of preparation thereof 30 Mar, 2036
Active
US10413543 Stable multiparticulate pharmaceutical composition of rosuvastatin 12 Feb, 2036
Active
US9700535 Oral pharmaceutical composition of isotretinoin 04 Aug, 2035
Active
US9750711 Low dose oral pharmaceutical composition of isotretinoin 29 May, 2035
Active
US9962336 Extended release suspension compositions 01 May, 2035
Active
US10292990 Abiraterone steroid formulation 20 May, 2034
Active
US9889144 Abiraterone acetate formulation and methods of use 17 Mar, 2034
Active
US10441630 Topical formulations and uses thereof 23 Aug, 2033
Active
US8980839 Topical aqueous nanomicellar, ophthalmic solutions and uses thereof 23 Aug, 2033
Active
US9937225 Topical formulations and uses thereof 23 Aug, 2033
Active
US9241948 Ready to be infused gemcetabine solution 01 Jul, 2033
Active
US8785427 Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives 25 Jul, 2030
Active
US8063043 Salts of N-[6-cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4′-(trifluoromethoxy)[1,1′-biphenyl]-3-carboxamide 15 Sep, 2029
Active
US9629852 Ophthalmic composition comprising a prostaglandin 12 Sep, 2029
Active
US8778999 Non-steroidal anti-inflammatory ophthalmic compositions 07 Aug, 2029
Active
US8178563 Compounds and compositions as hedgehog pathway modulators 24 Jul, 2029
Active
US9433628 Enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives 28 Feb, 2029
Active
US11207332 Enzymatic process for obtaining 17 α-monoesters of cortexolone and/or its 9,11-dehydroderivatives 20 Nov, 2028
Active
US9539262 Ophthalmic composition comprising a prostaglandin 15 Oct, 2028
Active
US10159682 Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives 14 Aug, 2028
Active
US11938141 Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives 24 Jul, 2028
Active
US9486458 Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives 24 Jul, 2028
Active
US8865690 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents 24 Jul, 2025
Active
US9211295 17 alpha, 21-dihydroxypregnene esters as antiandrogenic agents 31 May, 2025
Active
US8143240 17α, 21-dihydroxypregnene esters as antiandrogenic agents 12 Jan, 2025
Active


Given below is the list of recent legal activities going on the following drug patents of Sun Pharm.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 10 Jul, 2024 US9539262
Electronic Review 07 Jun, 2024 US11951153
Interim Patent Term Extension Granted 22 May, 2024 US9211295
Interim Patent Term Extension Granted 22 May, 2024 US8865690
Payment of Maintenance Fee, 8th Year, Large Entity 08 May, 2024 US9486458
Recordation of Patent eGrant 09 Apr, 2024 US11951153
Patent Issue Date Used in PTA Calculation 09 Apr, 2024 US11951153
Recordation of Patent Grant Mailed 09 Apr, 2024 US11951153
Mail Patent eGrant Notification 09 Apr, 2024 US11951153
Email Notification 09 Apr, 2024 US11951153
Patent eGrant Notification 09 Apr, 2024 US11951153
Email Notification 21 Mar, 2024 US11951153
Issue Notification Mailed 20 Mar, 2024 US11951153
Dispatch to FDC 07 Mar, 2024 US11951153
Email Notification 07 Mar, 2024 US11951153


Sun Pharm's Drug Patent Litigations

Sun Pharm's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jun 06, 2013, against patent number US9629852. The petitioner , challenged the validity of this patent, with Ajay Jaysingh Khopade et al as the respondent. Click below to track the latest information on how companies are challenging Sun Pharm's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US9629852 June, 2013 Decision
(26 Apr, 2016)
Ajay Jaysingh Khopade et al


Sun Pharm Drug Patents' Oppositions Filed in EPO

Sun Pharm drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 08, 2016, by Generics (U.K.) Limited. This opposition was filed on patent number EP13165862A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP15786792A Aug, 2021 Reckitt Benckiser Health Limited Granted and Under Opposition
EP13165862A Jan, 2016 Generics (U.K.) Limited Patent maintained as amended


Sun Pharm's Family Patents

Sun Pharm drugs have patent protection in a total of 58 countries. It's US patent count contributes only to 19.8% of its total global patent coverage. 15 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Sun Pharm Drug List

Given below is the complete list of Sun Pharm's drugs and the patents protecting them.


1. Absorica Ld

Absorica Ld is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9700535 Oral pharmaceutical composition of isotretinoin 04 Aug, 2035
(10 years from now)
Active
US9750711 Low dose oral pharmaceutical composition of isotretinoin 29 May, 2035
(10 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Absorica Ld's drug page


2. Bromsite

Bromsite is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8778999 Non-steroidal anti-inflammatory ophthalmic compositions 07 Aug, 2029
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bromsite's drug page


3. Bynfezia Pen

Bynfezia Pen is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10342850 Octreotide injection 15 May, 2038
(13 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bynfezia Pen's drug page


4. Cequa

Cequa is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10918694 Topical cyclosporine-containing formulations and uses thereof 28 Feb, 2037
(12 years from now)
Active
US11951153 Topical cyclosporine-containing formulations and uses thereof 28 Feb, 2037
(12 years from now)
Active
US10441630 Topical formulations and uses thereof 23 Aug, 2033
(8 years from now)
Active
US8980839 Topical aqueous nanomicellar, ophthalmic solutions and uses thereof 23 Aug, 2033
(8 years from now)
Active
US9937225 Topical formulations and uses thereof 23 Aug, 2033
(8 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cequa's drug page


5. Drizalma Sprinkle

Drizalma Sprinkle is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10413525 Duloxetine sprinkles 13 Apr, 2037
(12 years from now)
Active
US10959982 Duloxetine sprinkles 13 Apr, 2037
(12 years from now)
Active
US11202772 Duloxetine sprinkles 13 Apr, 2037
(12 years from now)
Active
US9839626 Duloxetine sprinkles 13 Apr, 2037
(12 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Drizalma Sprinkle's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Ezallor Sprinkle

Ezallor Sprinkle is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10413543 Stable multiparticulate pharmaceutical composition of rosuvastatin 12 Feb, 2036
(11 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ezallor Sprinkle's drug page


7. Infugem

Infugem is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9241948 Ready to be infused gemcetabine solution 01 Jul, 2033
(8 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Infugem's drug page


8. Odomzo

Odomzo is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10266523 Crystaline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-Methyl-4′-(trifluoromethoxy) [1,1′-biphenyl]-3-Methanamide monophosphate, and process of preparation thereof 30 Mar, 2036
(11 years from now)
Active
US8063043 Salts of N-[6-cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4′-(trifluoromethoxy)[1,1′-biphenyl]-3-carboxamide 15 Sep, 2029
(4 years from now)
Active
US8178563 Compounds and compositions as hedgehog pathway modulators 24 Jul, 2029
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Odomzo's drug page


9. Riomet Er

Riomet Er is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9962336 Extended release suspension compositions 01 May, 2035
(10 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Riomet Er's drug page


10. Winlevi

Winlevi is protected by 9 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8785427 Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives 25 Jul, 2030
(5 years from now)
Active
US9433628 Enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives 28 Feb, 2029
(4 years from now)
Active
US11207332 Enzymatic process for obtaining 17 α-monoesters of cortexolone and/or its 9,11-dehydroderivatives 20 Nov, 2028
(4 years from now)
Active
US10159682 Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives 14 Aug, 2028
(3 years from now)
Active
US11938141 Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives 24 Jul, 2028
(3 years from now)
Active
US9486458 Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives 24 Jul, 2028
(3 years from now)
Active
US8865690 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents 24 Jul, 2025
(9 months from now)
Active
US9211295 17 alpha, 21-dihydroxypregnene esters as antiandrogenic agents 31 May, 2025
(7 months from now)
Active
US8143240 17α, 21-dihydroxypregnene esters as antiandrogenic agents 12 Jan, 2025
(3 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Winlevi's drug page


11. Xelpros

Xelpros is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9629852 Ophthalmic composition comprising a prostaglandin 12 Sep, 2029
(4 years from now)
Active
US9539262 Ophthalmic composition comprising a prostaglandin 15 Oct, 2028
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xelpros's drug page


12. Yonsa

Yonsa is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10292990 Abiraterone steroid formulation 20 May, 2034
(9 years from now)
Active
US9889144 Abiraterone acetate formulation and methods of use 17 Mar, 2034
(9 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Yonsa's drug page